TVTXTravere Therapeutics, Inc.

1. Sep 21, 2026On September 21, 2026, Travere Therapeutics, Inc. (the “Company”) and Eric Dube, Ph.D., mutually agreed to the timeline and terms surrounding the planned transition of Dr. Dube, who will step down from his position as the Company’s President and Chief Executive Officer and as a member of the Board of Directors of the …Director or officer change · Form 8-K
2. Aug 4, 2026Travere Therapeutics Reports Second Quarter 2026 Financial Results.Earnings release · press release
3. Jul 9, 20265.02(b) On July 6, 2026, Sandra Calvin, chief accounting officer (CAO) and principal accounting officer (PAO) of the Company, provided notice to the Company of her intention to retire from employment with the Company following the filing of the Company’s Annual Report on Form 10-K expected in February 2027 (the …Director or officer change · Form 8-K
4. Jun 16, 2026On June 12, 2026, William Rote, Ph.D., Chief Research Officer of the Company, provided notice to the Company of his intention to retire from employment with the Company, effective February 17, 2027 (the “Retirement Date”), the 10 year anniversary of his employment with the Company.Director or officer change · Form 8-K
5. Jun 2, 2026On June 1, 2026, Travere Therapeutics, Inc. (the “Company”) entered into a license and collaboration agreement (the “Agreement”) with Everest Medicines (Singapore) Pte.Material agreement entered · Form 8-K
6. May 21, 2026, Travere Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) at which the Company’s stockholders approved the Company’s 2018 Equity Incentive Plan, as amended (the “2018 Plan”), to increase the number of shares of common stock authorized for issuance thereunder by …Director or officer change · Form 8-K
7. May 11, 2026Completion of Senior Convertible Notes Offering On May 11, 2026 (the “Closing Date”), Travere Therapeutics, Inc. (the “Company”) completed its registered underwritten public offering of $525.0 million aggregate principal amount of 0.50% Convertible Senior Notes due 2032 (such notes, the “Notes,” and such offering, the …Material agreement entered · Form 8-K
8. May 4, 2026Travere Therapeutics Reports First Quarter 2026 Financial Results.Earnings release · press release
9. Apr 14, 2026On April 13, 2026, Travere Therapeutics, Inc. (the “Company”) announced that the U.S. Food and Drug Administration (“FDA”) has approved FILSPARI® (sparsentan) to reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis (“FSGS”) without nephrotic syndrome.Other event · Form 8-K
10. Feb 19, 2026Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results.Earnings release · press release
11. Jan 13, 2026On January 13, 2026, Travere Therapeutics, Inc. (the “Company”) announced that the U.S. Food and Drug Administration (“FDA”) has extended the review timeline of its supplemental New Drug Application (“sNDA”) for FILSPARI® (sparsentan) in focal segmental glomerulosclerosis (“FSGS”)Other event · Form 8-K
12. Jan 12, 2026Travere Therapeutics Provides Corporate Update and 2026 Outlook.Earnings release · press release

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.